CA-CROWN-BIOSCIENCE
Crown Bioscience, a global contract research organization (CRO) and a JSR Life Sciences company, will showcase significant contributions in preclinical and translational oncology research at the American Association for Cancer Research (AACR) 2024 meeting. Highlighting its latest research, the company will present ten posters covering a broad spectrum of data from the company's R&D program.
The data presented will cover a range of innovative techniques in oncology and immuno-oncology drug discovery and development. Posters featured at AACR include:
- The in-depth Characterization of Acute Myeloid Leukemia Patient-Derived Xenograft (PDX) Models with Hotspot Gene Mutations for Therapeutic Evaluation.
- The development of an Integrated Pipeline for Immuno-Oncology Drug Testing, using patient-derived tumor organoids with a reconstituted tumor microenvironment and fresh ex vivo patient tissue cultures, aiming to enhance therapeutic evaluation and drug development efficiency with translational patient-derived systems.
- The utilization of Large Panel Organoid Drug Testing Combined with Biomarker Analysis, set to deliver insights into mechanisms of action and boost efficiency within the drug development pipeline.
- Research on KRAS Inhibitors and PARP Inhibitor-Induced Resistant PDX Ovarian Cancer Models further expands on the knowledge base of drug resistance patterns in cancer while also assessing innovative therapeutic approaches for targeting mutated tumors, including combination therapy.
- SynAI, an adaptive AI-driven platform for in silico drug synergism screening, optimizes the exploration of compound interactions in early-stage cancer drug development.
- Magnetic Resonance Imaging and Bioluminescence Imaging for Evaluating Tumor Burden in Orthotopic Glioblastoma, merging digital technology with cancer research to forecast a new era of therapeutic strategy development.
Abstracts for all ten poster presentations can be found on a dedicated page, Crown Bioscience AACR posters 2024. Following the show, all will be available for download.
Attendees are encouraged to visit Booth #1717 to learn more about these studies and talk to Crown Bioscience’s scientists to gain deeper insights into the platforms and services on offer to advance oncology research.
About Crown Bioscience
Crown Bioscience, a JSR Life Sciences company, is a global Contract Research Organization (CRO) partnering with biotech and pharmaceutical companies to rapidly advance the discovery and development of oncology drugs. As the exclusive preclinical CRO providing tumor organoid services with the well-established Hubrecht Organoid Technology, we offer over 600 organoid models spanning 22 cancer indications. Furthermore, we have developed the world’s largest commercially available PDX collection. Our focus on helping our customers develop novel therapies aims to ensure that patients receive the right treatment at the right time. Founded in 2006, we have 13 facilities across the US, Europe, and Asia. For more information, please visit www.crownbio.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240328082232/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
SkySparc Acquires Inovotek Solutions to Strengthen Its Capital Markets Expertise and Expand Delivery Across Murex, Calypso, and FIS Platforms15.10.2025 09:00:00 CEST | Press release
SkySparc, a trusted global provider of digital transformation solutions for treasury and finance institutions, today announced the acquisition of Inovotek Solutions (“Inovotek” or the “Company”), a specialist provider of transformation services to capital markets and financial institutions. Financial terms were not disclosed. The acquisition will bolster SkySparc's position as a premier provider of comprehensive digital transformation services to capital markets clients globally. It will address critical client challenges, including regulatory compliance and complex re-platforming initiatives. Additionally, SkySparc will expand its expertise across leading trading and risk management platforms such as Murex, Calypso, and FIS. By combining Inovotek’s program management expertise with SkySparc’s established managed services and proprietary software – OmniFi and Optimizer – the Company will deliver a robust and complete offering capable of addressing the most complex and demanding client
Usercentrics Surpasses €100M ARR ($117M USD) as Market Leader in Data Privacy, Paving the Way for Privacy-Led Marketing15.10.2025 08:00:00 CEST | Press release
The marketing playbook is being rewritten. AI is accelerating, and consumers want more control than ever. In this new reality, privacy isn’t a constraint - it’s the currency of trust. Usercentrics today announced it surpassed €100 million in Annual Recurring Revenue (ARR), approximately $117 million USD in late August, to the tune of profitable 45% YoY growth,powered by millions of users. This milestone elevates Usercentrics into the elite “centaur” category - SaaS companies generating over €100 million in recurring revenue annually. With fewer than 200 private companies worldwide at this level, centaur status is increasingly viewed as a more meaningful benchmark than unicorn valuations, which can be inflated by high multiples on lower revenues. The milestone cements Usercentrics’ position as the leader of a new marketing era: Privacy-Led Marketing - trusted by millions of users worldwide and strengthened through strategic partnerships with global technology leaders, including Google,
IFF to Release Third Quarter 2025 Results on Nov. 4, 202514.10.2025 22:15:00 CEST | Press release
IFF (NYSE:IFF) today announced that it will release its third quarter 2025 earnings results following the market close on Tuesday, Nov. 4, 2025. The management team will host a live webcast on Wednesday, Nov. 5, 2025, at 9:00 a.m. ET to discuss results and outlook with the investor community. Investors may access the live webcast and accompanying slide presentation on the Company's website at ir.iff.com. For those unable to listen to the live webcast, a recorded version will be made available for replay. Welcome to IFF At IFF (NYSE: IFF), we make joy through science, creativity and heart. As the global leader in flavors, fragrances, food ingredients, health and biosciences, we deliver groundbreaking, sustainable innovations that elevate everyday products—advancing wellness, delighting the senses and enhancing the human experience.Learn more at iff.com, LinkedIn, Instagram and Facebook. View source version on businesswire.com: https://www.businesswire.com/news/home/20251014533502/en/
TRU Simulation and US Aviation Academy sign purchase agreement for five Cessna Skyhawk Veris Virtual Reality Simulators, signifying first fleet order and fixed-wing market debut14.10.2025 20:39:00 CEST | Press release
During the National Business Aviation Association – Business Aviation Convention & Exhibition (NBAA-BACE), TRU Simulation + Training Inc., a Textron Inc.(NYSE:TXT) company, and an affiliate of Textron Aviation Inc., announced an agreement with the US Aviation Academy for its purchase of five of TRU Simulation’s Cessna Skyhawk Veris Virtual Reality (VR) Simulators. This landmark agreement introduces the Veris to the fixed-wing training market and is TRU Simulation’s first fleet order for VR training devices. The US Aviation Academy has the option for a future purchase of ten additional units as part of the agreement, underscoring a shared commitment to advancing pilot training through cutting-edge VR simulation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251013144401/en/ TRU Simulation and US Aviation Academy sign purchase agreement for five Cessna Skyhawk Veris Virtual Reality Simulators, signifying first fleet order and
Introducing Lasso: A New Food Tech Company Redefining Consumer Packaged Foods14.10.2025 19:34:00 CEST | Press release
Backed by $6.5M in new funding, Lasso is filling a void in the food industry with its proprietary fiber spinning technology that transforms simple ingredients into clean-label, protein-packed foods. Lasso today announced its official launch and the introduction of its proprietary technology, Lasso SpinTech. This breakthrough system upends the outdated standards of ultra-processed foods using physics to weave together protein and fiber to make previously unattainable new consumer products. With a new $6.5M raise, Lasso is bringing its technology to the world by launching its own brands and licensing to global partners to create a new generation of healthier foods. Guided by CEO Mike Messersmith, the Lasso team spent the past year deploying its commercial-scale technology to create innovative clean-label products including protein-packed snacks and pet food—expanding beyond its first plant-based meat application under the Tender Food brand. Lasso’s latest $6.5M in capital, led by Rhapsod
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom